TZ9 is an inhibitor of Rad6B expressing human breast cancer cell lines MDA-MB-231 and MCF-7. It is also the first competitive E2-ligase inhibitor that acts by blocking thioester formation. References: Nethi SK, P NAA, Rico-Oller B, Rodríguez-Diéguez A, Gómez-Ruiz S, Patra CR. Design, synthesis and characterization of doped-titanium oxide nanomaterials with environmental and angiogenic applications. Sci Total Environ. 2017 Dec 1;599-600:1263-1274. doi: 10.1016/j.scitotenv.2017.05.005. Epub 2017 May 15. PubMed PMID: 28525935.

纯度：≥98%

CAS：1002789-86-7